Beyond the headline drugs, four mechanisms are being tested right now: amyloid clearance, tau stabilization, neuroinflammation modulators, and GLP-1-adjacent metabolic pathways. The data isn’t equally strong across all four, and one of them is a surprise.
The more interesting question is what happens to the amyloid hypothesis if one of the non-amyloid paths reads out positive first.
